The Medicines Patent Pool (MPP), a “one-stop shop” for patented medicines owned by different companies and made available for voluntary licensing in low- and middle-income countries, has struck an agreement with Cipla Ltd. under which India’s third-largest generic drug company will develop, manufacture and supply HIV treatment lopinavir (LPV) and ritonavir (RTV) for pediatric use.
Cipla will make LPV and RTV individually or in combination for pediatric use under the sub-licensing deal
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?